Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients

H. Chang, SunYoung Rha, H. C. Jeung, C. K. Im, J. B. Ahn, W. S. Kwon, N. C. Yoo, J. K. Roh, Hyuncheol Chung

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background: ABCB1 is responsible for multidrug resistance, the principal mechanism by which many cancers develop resistance to chemotherapeutic drugs. There is a controversy whether ABCB1 gene polymorphisms correlate with survival and response in cancer patients treated with chemotherapy. We evaluated the association between clinical outcome (safety and efficacy) of paclitaxel monotherapy in metastatic breast cancer patients with ABCB1 gene polymorphisms 2677G>T/A or 3435C>T. Patients and methods: Patients with metastatic breast cancer were treated with 175 mg/m 2 paclitaxel per 3-week cycle. Peripheral blood mononuclear cells from patients were used to genotype ABCB1 2677G>T/A and 3435C>T polymorphisms. Genotypes were investigated for their association with tumor response, survival, toxicity, and chemoresistance. Results: ABCB1 3435 CT showed a significantly lower disease control rate than the CC genotype (P = 0.025). ABCB1 3435 CT was correlated with shorter overall survival (OS) in Cox regression analysis (P = 0.026). The 2677 GG genotype showed a significant association with chemoresistance to paclitaxel and anthracycline (P = 0.04 and 0.04, respectively). None of the ABCB1 genotypes correlated with toxicity. Conclusions: ABCB1 genotypes may be a predictor of paclitaxel activity as well as a prognostic factor in metastatic breast cancer patients.

Original languageEnglish
Pages (from-to)272-277
Number of pages6
JournalAnnals of Oncology
Volume20
Issue number2
DOIs
Publication statusPublished - 2009 Feb 25

Fingerprint

Paclitaxel
Genotype
Breast Neoplasms
Genes
Survival
Neoplasms
Anthracyclines
Multiple Drug Resistance
Blood Cells
Regression Analysis
Safety
Drug Therapy
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Chang, H. ; Rha, SunYoung ; Jeung, H. C. ; Im, C. K. ; Ahn, J. B. ; Kwon, W. S. ; Yoo, N. C. ; Roh, J. K. ; Chung, Hyuncheol. / Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. In: Annals of Oncology. 2009 ; Vol. 20, No. 2. pp. 272-277.
@article{3099592215934c25a456ed641d00e573,
title = "Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients",
abstract = "Background: ABCB1 is responsible for multidrug resistance, the principal mechanism by which many cancers develop resistance to chemotherapeutic drugs. There is a controversy whether ABCB1 gene polymorphisms correlate with survival and response in cancer patients treated with chemotherapy. We evaluated the association between clinical outcome (safety and efficacy) of paclitaxel monotherapy in metastatic breast cancer patients with ABCB1 gene polymorphisms 2677G>T/A or 3435C>T. Patients and methods: Patients with metastatic breast cancer were treated with 175 mg/m 2 paclitaxel per 3-week cycle. Peripheral blood mononuclear cells from patients were used to genotype ABCB1 2677G>T/A and 3435C>T polymorphisms. Genotypes were investigated for their association with tumor response, survival, toxicity, and chemoresistance. Results: ABCB1 3435 CT showed a significantly lower disease control rate than the CC genotype (P = 0.025). ABCB1 3435 CT was correlated with shorter overall survival (OS) in Cox regression analysis (P = 0.026). The 2677 GG genotype showed a significant association with chemoresistance to paclitaxel and anthracycline (P = 0.04 and 0.04, respectively). None of the ABCB1 genotypes correlated with toxicity. Conclusions: ABCB1 genotypes may be a predictor of paclitaxel activity as well as a prognostic factor in metastatic breast cancer patients.",
author = "H. Chang and SunYoung Rha and Jeung, {H. C.} and Im, {C. K.} and Ahn, {J. B.} and Kwon, {W. S.} and Yoo, {N. C.} and Roh, {J. K.} and Hyuncheol Chung",
year = "2009",
month = "2",
day = "25",
doi = "10.1093/annonc/mdn624",
language = "English",
volume = "20",
pages = "272--277",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. / Chang, H.; Rha, SunYoung; Jeung, H. C.; Im, C. K.; Ahn, J. B.; Kwon, W. S.; Yoo, N. C.; Roh, J. K.; Chung, Hyuncheol.

In: Annals of Oncology, Vol. 20, No. 2, 25.02.2009, p. 272-277.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients

AU - Chang, H.

AU - Rha, SunYoung

AU - Jeung, H. C.

AU - Im, C. K.

AU - Ahn, J. B.

AU - Kwon, W. S.

AU - Yoo, N. C.

AU - Roh, J. K.

AU - Chung, Hyuncheol

PY - 2009/2/25

Y1 - 2009/2/25

N2 - Background: ABCB1 is responsible for multidrug resistance, the principal mechanism by which many cancers develop resistance to chemotherapeutic drugs. There is a controversy whether ABCB1 gene polymorphisms correlate with survival and response in cancer patients treated with chemotherapy. We evaluated the association between clinical outcome (safety and efficacy) of paclitaxel monotherapy in metastatic breast cancer patients with ABCB1 gene polymorphisms 2677G>T/A or 3435C>T. Patients and methods: Patients with metastatic breast cancer were treated with 175 mg/m 2 paclitaxel per 3-week cycle. Peripheral blood mononuclear cells from patients were used to genotype ABCB1 2677G>T/A and 3435C>T polymorphisms. Genotypes were investigated for their association with tumor response, survival, toxicity, and chemoresistance. Results: ABCB1 3435 CT showed a significantly lower disease control rate than the CC genotype (P = 0.025). ABCB1 3435 CT was correlated with shorter overall survival (OS) in Cox regression analysis (P = 0.026). The 2677 GG genotype showed a significant association with chemoresistance to paclitaxel and anthracycline (P = 0.04 and 0.04, respectively). None of the ABCB1 genotypes correlated with toxicity. Conclusions: ABCB1 genotypes may be a predictor of paclitaxel activity as well as a prognostic factor in metastatic breast cancer patients.

AB - Background: ABCB1 is responsible for multidrug resistance, the principal mechanism by which many cancers develop resistance to chemotherapeutic drugs. There is a controversy whether ABCB1 gene polymorphisms correlate with survival and response in cancer patients treated with chemotherapy. We evaluated the association between clinical outcome (safety and efficacy) of paclitaxel monotherapy in metastatic breast cancer patients with ABCB1 gene polymorphisms 2677G>T/A or 3435C>T. Patients and methods: Patients with metastatic breast cancer were treated with 175 mg/m 2 paclitaxel per 3-week cycle. Peripheral blood mononuclear cells from patients were used to genotype ABCB1 2677G>T/A and 3435C>T polymorphisms. Genotypes were investigated for their association with tumor response, survival, toxicity, and chemoresistance. Results: ABCB1 3435 CT showed a significantly lower disease control rate than the CC genotype (P = 0.025). ABCB1 3435 CT was correlated with shorter overall survival (OS) in Cox regression analysis (P = 0.026). The 2677 GG genotype showed a significant association with chemoresistance to paclitaxel and anthracycline (P = 0.04 and 0.04, respectively). None of the ABCB1 genotypes correlated with toxicity. Conclusions: ABCB1 genotypes may be a predictor of paclitaxel activity as well as a prognostic factor in metastatic breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=60549112572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549112572&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdn624

DO - 10.1093/annonc/mdn624

M3 - Article

VL - 20

SP - 272

EP - 277

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -